These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22067201)

  • 1. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
    Keller SB; Smith DM
    AIDS; 2011 Nov; 25(18):2308-10. PubMed ID: 22067201
    [No Abstract]   [Full Text] [Related]  

  • 2. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
    Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J
    Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
    King HL; Keller SB; Giancola MA; Rodriguez DA; Chau JJ; Young JA; Little SJ; Smith DM
    AIDS Behav; 2014 Sep; 18(9):1722-5. PubMed ID: 25017425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preexposure chemoprophylaxis for HIV prevention.
    Lee DH; Vielemeyer O
    N Engl J Med; 2011 Apr; 364(14):1372-3; author reply 1374-5. PubMed ID: 21470026
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA paves the way for pre-exposure HIV prophylaxis.
    Holmes D
    Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
    Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions of emtricitabine-tenofovir in HIV PrEP.
    Kruse L; Stover K; Henderson H
    HIV Clin; 2014; 26(1):1, 4-7. PubMed ID: 24855688
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Still a long wait for approved HIV-protective gel.
    Bateman C
    S Afr Med J; 2010 Sep; 100(9):560, 562. PubMed ID: 20822637
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing HIV in women--still trying to find their VOICE.
    Saag MS
    N Engl J Med; 2015 Feb; 372(6):564-6. PubMed ID: 25651251
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing initial therapy for HIV infection.
    Hull MW; Montaner JS
    J Infect Dis; 2011 Oct; 204(8):1154-6. PubMed ID: 21917886
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
    Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
    Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
    PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.